Pipeline

We are building a pipeline of highly differentiated multi-specific drug discovery and development programs based on our unique λ-Cap™ & MATCH™ proprietary technologies. Numab is striving to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines for patients suffering from serious diseases.

Pipeline Inflammation

Research
Preclinical
Phase I
Phase II
Partner
NM26
Atopic Dermatitis
Kaken

NM26-2198 is a bispecific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis, or AD. NM26-2198 is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. The targeting of the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Numab develops this program together with its regional partner in Japan, Kaken Pharmaceutical.

ND059
Ophthalmology
Boehringer
Ingelheim

ND059 is a collaboration project partnered with Boehringer Ingelheim to develop a candidate against geographic atrophy, a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.

NM09
Ulcerative Colitis
Tillotts

NM09 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease (IBD), a chronic inflammation of the digestive tract that primarily includes ulcerative colitis and Crohn’s disease. Anti-TNF therapy has been shown to reduce the need for hospitalization and surgical interventions in IBD and improve quality of life. Numab’s highly stable antibody fragment NM009 has best-in-class potency and is licensed to Tillotts Pharma for the development and commercialization of innovative formulations.

Multiple Programs
Inflammation

Numab is developing multiple proprietary inflammation programs utilizing our versatile, multi-specific MATCH™ platform. We are combining antagonism of multiple  disease-driving pathways to create innovative, multi-functional drug candidates. With these rationally designed drug candidates we seek to exceed the reaches of current standard of care medication in inflammatory diseases to provide much needed improvement in the quality of life for patients.

Pipeline Oncology

Research
Preclinical
Phase I
Phase II
Partner
NM32
Solid Tumors

NM32-2668 is a tri-specific anti-ROR1/CD3/HSA antibody based on our scMATCH3 format. NM32-2668 induces T cell-mediated lysis of tumors expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). Binding to human serum albumin (HSA) prolongs the half-life of the molecule in circulation and supports a convenient dosing scheme. ROR1 is overexpressed on a variety of difficult to treat tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), triple-negative breast cancer (TNBC), lung cancer, and ovarian cancer. ROR1-expressing hematologic and solid tumors display a high potential for self-renewal, increased survival, and migration, and are associated with poor outcomes.

ND037
Oncology
Eisai

ND037 refers to an undisclosed number of discovery projects partnered with Eisai, aimed at the identification of novel multi-specific antibody fragment-based molecules for immuno-oncology.

 

ND038
Oncology
Eisai

ND038 is a collaboration project partnered with Eisai, with the goal of leveraging Numab’s multi-specific technology to generate a cancer therapeutic that provides superior efficacy and safety compared to benchmark immunotherapies.

NM23
Oncology
Ono

NM23 is a collaboration project partnered with Ono Pharmaceutical, (the originator of the anti-PD1 antibody Nivolumab/Opdivo®) aimed at the discovery of a multi-specific antibody fragment-based molecule for immuno-oncology.

ND039
Oncology
Ono

ND039 is a collaboration project partnered with Ono Pharmaceutical, (the originator of the anti-PD1 antibody Nivolumab/Opdivo®) aimed at the discovery of a multi-specific antibody fragment-based molecule for immuno-oncology.

ND047
Oncology
Boehringer
Ingelheim

ND047 is a collaboration project partnered with Boehringer Ingelheim with the goal to develop a T-cell engager for the treatment of gastrointestinal cancer based on Numab’s multi-specific antibody platform.

NM49
Oncology
Ono

NM49 is a multi-specific antibody designed to activate anti-tumor immune responses, and in particular tumor associated macrophage phagocytosis. The program is partnered with Ono Pharmaceutical under a research and license option agreement. Numab has an option to co-develop NM49 with profit split arrangement in the United States.

Multiple Programs
Oncology

Numab is developing multiple proprietary immuno-oncology programs utilizing our versatile, multi-specific MATCH™ platform. We are combining immune effector functions, immune-checkpoint antagonism, and cancer-specific targeting to create innovative, multi-functional drug candidates. These drug candidates are rationally designed to activate key components of the innate and adaptive immune system to bring significant improvement to the lives of cancer patients.

Partners

Boehringer Ingelheim

In July 2020, Numab and Boehringer Ingelheim announced a research collaboration and worldwide licensing agreement. It will start with two…

In July 2020, Numab and Boehringer Ingelheim announced a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life-changing breakthrough therapies with Numab’s multi-specific antibody platform. Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each indication. Boehringer Ingelheim received from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.

For more information on Boehringer Ingelheim, please visit: https://www.boehringer-ingelheim.com/

Eisai

In October 2019, Numab and Eisai announced a research and option agreement to discover and develop novel multi-specific antibody immunotherapies…

In October 2019, Numab and Eisai announced a research and option agreement to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform. Under the terms of the agreement, Eisai has the option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules that emerge from the joint research collaboration. In exchange, Numab received an upfront payment in addition to research funding and is eligible to receive success fees, milestone payments, and tiered royalties on product sales.

For more information about Eisai, please visit: www.eisai.com

CStone Pharmaceuticals

In May 2019, Numab entered into an exclusive regional licensing agreement for the development and commercialization of its most advanced…

In May 2019, Numab entered into an exclusive regional licensing agreement for the development and commercialization of its most advanced proprietary asset NM21 with CStone Pharmaceuticals. Pursuant to the terms of the licensing agreement, CStone funds the research and development of NM21, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and serum albumin, up to completion of a first Phase 1b clinical trial. In exchange, CStone obtains exclusive rights to develop and commercialize NM21 in Greater China, including Mainland China, Hong Kong, Macau, and Taiwan, as well as South Korea and Singapore. Numab retains all NM21 rights for the rest of the world. Upon completion of CStone’s funding period, no further financial obligations will be owed by either party.

For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com

Ono Pharmaceutical

In March 2022, Numab announced a development and license agreement with Ono Pharmaceutical granting Ono exclusive rights to develop and…

In March 2022, Numab announced a development and license agreement with Ono Pharmaceutical granting Ono exclusive rights to develop and commercialize a multispecific antibody candidate in immuno-oncology resulting from Numab’s research program NM23. NM23 was initiated under a research and option agreement concluded between Ono and Numab in 2017. In consideration for the discovery work and the license, Numab is eligible for up to CHF 258 million in research funding, upfront and milestone payments plus tiered single to double digit royalties on future sales.

In March 2020, Numab and Ono expanded their collaboration with a second multi-specific antibody drug program (ND039) for the treatment of various cancers. The financial terms involved in this second program largely match those of the initial collaboration, essentially doubling the potential commercial value of the relationship for Numab.

For more information about Ono Pharmaceutical, please visit www.ono.co.jp

Kaken Pharmaceutical

In January 2021, Numab announced a global co-development and regional license agreement with Kaken Pharmaceutical for the company’s novel multispecific…

In January 2021, Numab announced a global co-development and regional license agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory , which blocks three key pathways in the pathophysiology of atopic dermatitis. Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

The alliance builds on a collaboration and option agreement established in 2017.

For more information about Kaken Pharmaceutical, please visit www.kaken.co.jp

 

Tillotts Pharma

In June 2015, Numab and Tillotts Pharma announced an exclusive global license agreement to develop and commercialize antibody-based therapies that…

In June 2015, Numab and Tillotts Pharma announced an exclusive global license agreement to develop and commercialize antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). In 2023 Tillotts has spun this program into newly formed Mage Biologics that continues to clinically develop an orally administered anti-TNF antibody identified by Numab as part of the NM09 program. Numab is eligible to milestone payments and royalties on net sales.

For more information about Tillots Pharma, please visit www.tillotts.com.

Stay informed.

Cookies: OK! Privacy Statement